Silver Book Fact

“Sherri Selph was 41 when she was first diagnosed with second-stage congestive heart failure. However, her rapidly diminishing health led to a diagnosis of end-stage heart disease. A heart transplant was not an option. Survival statistics for patients with Sherrie’s condition are grim. Even with the best treatment available, only 50 percent of heart failure patients live beyond a year.
Her doctor suggested that Sherri enroll in a clinical trial. Sherri soon became a patient and a member of the group that received an implantable heart pump.
The results were immediate. Four days after receiving her heart pump Sherri was back on her feet. ‘I could not believe it. The pump had given me back my life,’ she said. ‘Without this procedure, I would not have lived to see my youngest grandson who is now two and a half years old.’ Sherri is now back in South Carolina with her heart pump and her five grand-children, who prefer that she stay right where she is.”

Investment in Research Saves Lives and Money. http://www.researchamerica.org/advocacy/investment.html. Published 2005

Reference

Title
Investment in Research Saves Lives and Money
Publisher
Research!America
Publication Date
Published 2005
Authors
Research!America
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Effect of optimal anticoagulation
    If 50% of atrial fibrillation patients who currently receive warfarin in routine medical care were optimally anticoagulated, 9,852 emboli would be prevented and $1.3 billion would be saved each year.  
  • The greater use of medications and revascularization would provide approximately a 17% reduction in 2 year mortality combined.  
  • The age-adjusted stroke mortality rate has decreased 70% since 1950, and 64% since 1972.  
  • Every additional dollar spent on antiplatelet therapy versus aspirin for the prevention of stroke in high-risk patients, has produced health gains valued between $2 and $6.  
  • TAVR Success in sSAS Patients
    A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,…